Targeting the undruggable in glioblastoma using nano-based intracellular drug delivery.

Humans Glioblastoma / drug therapy Brain Neoplasms / drug therapy Drug Delivery Systems / methods Antineoplastic Agents / administration & dosage Blood-Brain Barrier / metabolism Nanoparticles / administration & dosage Animals Nanoparticle Drug Delivery System Genetic Therapy / methods
Drug delivery Glioblastoma (GBM) Nanoparticles (NPs) Targeting Undruggable

Journal

Medical oncology (Northwood, London, England)
ISSN: 1559-131X
Titre abrégé: Med Oncol
Pays: United States
ID NLM: 9435512

Informations de publication

Date de publication:
29 Oct 2024
Historique:
received: 31 07 2024
accepted: 17 10 2024
medline: 29 10 2024
pubmed: 29 10 2024
entrez: 29 10 2024
Statut: epublish

Résumé

Glioblastoma (GBM) is a highly prevalent and aggressive brain tumor in adults with limited treatment response, leading to a 5-year survival rate of less than 5%. Standard therapies, including surgery, radiation, and chemotherapy, often fall short due to the tumor's location, hypoxic conditions, and the challenge of complete removal. Moreover, brain metastases from cancers such as breast and melanoma carry similarly poor prognoses. Recent advancements in nanomedicine offer promising solutions for targeted GBM therapies, with nanoparticles (NPs) capable of delivering chemotherapy drugs or radiation sensitizers across the blood-brain barrier (BBB) to specific tumor sites. Leveraging the enhanced permeability and retention effect, NPs can preferentially accumulate in tumor tissues, where compromised BBB regions enhance delivery efficiency. By modifying NP characteristics such as size, shape, and surface charge, researchers have improved circulation times and cellular uptake, enhancing therapeutic efficacy. Recent studies show that combining photothermal therapy with magnetic hyperthermia using AuNPs and magnetic NPs induces ROS-dependent apoptosis and immunogenic cell death providing dual-targeted, immune-activating approaches. This review discusses the latest NP-based drug delivery strategies, including gene therapy, receptor-mediated transport, and multi-modal approaches like photothermal-magnetic hyperthermia combinations, all aimed at optimizing therapeutic outcomes for GBM.

Identifiants

DOI: 10.1007/s12032-024-02546-8 PMID: 39470962
pubmed: 39470962
doi: 10.1007/s12032-024-02546-8
pii: 10.1007/s12032-024-02546-8
doi:

Substances chimiques

Antineoplastic Agents 0
Nanoparticle Drug Delivery System 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

303

Informations de copyright

© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Références

Sheervalilou R, et al. Recent advances in iron oxide nanoparticles for brain cancer theranostics: from in vitro to clinical applications. Expert Opin Drug Deliv. 2021;18(7):949–77.
pubmed: 33567919 doi: 10.1080/17425247.2021.1888926
Johnson DR, et al. A radiologist’s guide to the 2021 WHO central nervous system tumor classification: part I—key concepts and the spectrum of diffuse gliomas. Radiology. 2022;304(3):494–508.
pubmed: 35880978 doi: 10.1148/radiol.213063
Park YW, Vollmuth P, Foltyn-Dumitru M, Sahm F, Choi KS, Park JE, Ahn SS, Chang JH, The KSH. WHO classification for gliomas and implications on imaging diagnosis: part 3—summary of imaging findings on glioneuronal and neuronal tumors. J Magn Res Imaging. 2021;58(6):1680–702.
doi: 10.1002/jmri.29016
Sheervalilou R, et al. Circulating MiR-10b, MiR-1 and MiR-30a expression profiles in lung cancer: possible correlation with clinico-pathologic characteristics and lung cancer detection. Int J Mol Cell Med. 2019;8(2):118.
pubmed: 32215263 pmcid: 7081081
Sheervalilou R, et al. Using miR-10b, miR-1 and miR-30a expression profiles of bronchoalveolar lavage and sputum for early detection of non-small cell lung cancer. Biomed Pharmacother. 2017;88:1173–82.
doi: 10.1016/j.biopha.2017.02.002
Shirvalilou S, et al. Development of a magnetic nano-graphene oxide carrier for improved glioma-targeted drug delivery and imaging: in vitro and in vivo evaluations. Chem Biol Interact. 2018;295:97–108.
pubmed: 30170108 doi: 10.1016/j.cbi.2018.08.027
Cerna T, et al. Nanocarrier drugs in the treatment of brain tumors. J Cancer Metastasis Treat. 2016;2:407–16.
doi: 10.20517/2394-4722.2015.95
Forst DA, et al. Low-grade gliomas. Oncologist. 2014;19(4):403–13.
pubmed: 24664484 pmcid: 3983820 doi: 10.1634/theoncologist.2013-0345
Jakola AS, et al. Surgical resection versus watchful waiting in low-grade gliomas. Ann Oncol. 2017;28(8):1942–8.
pubmed: 28475680 pmcid: 5834105 doi: 10.1093/annonc/mdx230
Panciani PP, et al. Fluorescence and image guided resection in high grade glioma. Clin Neurol Neurosurg. 2012;114(1):37–41.
pubmed: 21963142 doi: 10.1016/j.clineuro.2011.09.001
Darlix A, et al. Chemotherapy and diffuse low-grade gliomas: a survey within the European low-grade glioma network. Neuro-Oncol Practice. 2019;6(4):264–73.
doi: 10.1093/nop/npy051
Caffo M, et al. Nanoparticles drug-delivery systems and antiangiogenic approaches in the treatment of gliomas. Glioma. 2018;1(6):183.
doi: 10.4103/glioma.glioma_43_18
De Vries NA, et al. Blood–brain barrier and chemotherapeutic treatment of brain tumors. Expert Rev Neurother. 2006;6(8):1199–209.
pubmed: 16893347 doi: 10.1586/14737175.6.8.1199
Régina A, et al. Multidrug resistance in brain tumors: roles of the blood–brain barrier. Cancer Metastasis Rev. 2001;20:13–25.
pubmed: 11831641 doi: 10.1023/A:1013104423154
Tavares MR, et al. Polymeric nanoparticles assembled with microfluidics for drug delivery across the blood-brain barrier. European Phys J Spec Topics. 2016;225(4):779–95.
doi: 10.1140/epjst/e2015-50266-2
Batista CAS, Larson RG, Kotov NA. Nonadditivity of nanoparticle interactions. Science. 2015. https://doi.org/10.1126/science.1242477 .
doi: 10.1126/science.1242477 pubmed: 26450215
Shi J, et al. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017;17(1):20–37.
pubmed: 27834398 doi: 10.1038/nrc.2016.108
Almanghadim HG, et al. Application of nanoparticles in cancer therapy with an emphasis on cell cycle. Cell Biol Int. 2021;45(10):1989–98.
pubmed: 34233087 doi: 10.1002/cbin.11658
Kafshdooz L, et al. Labour analgesia; molecular pathway and the role of nanocarriers: a systematic review. Artificial Cells, Nanomedicine, and Biotechnology. 2019;47(1):927–32.
pubmed: 30873885 doi: 10.1080/21691401.2019.1573736
Ghaznavi H, et al. Effects of folate-conjugated Fe2O3@ Au core–shell nanoparticles on oxidative stress markers, DNA damage, and histopathological characteristics: evidence from in vitro and in vivo studies. Med Oncol. 2022;39(9):122.
pubmed: 35716197 doi: 10.1007/s12032-022-01713-z
Mirzaghavami PS, et al. Folic acid-conjugated magnetic triblock copolymer nanoparticles for dual targeted delivery of 5-fluorouracil to colon cancer cells. Cancer Nanotechnology. 2022;13(1):12.
doi: 10.1186/s12645-022-00120-3
Senapati S, et al. Controlled drug delivery vehicles for cancer treatment and their performance. Signal Transduct Target Ther. 2018;3(1):1–19.
Shusta EV. Blood-brain barrier genomics, proteomics, and new transporter discovery. NeuroRx. 2005;2(1):151–61.
pubmed: 15717066 pmcid: 539336 doi: 10.1602/neurorx.2.1.151
Rip J, Schenk GJ, De Boer AG. Differential receptor-mediated drug targeting to the diseased brain. Expert Opin Drug Deliv. 2009;6(3):227–37.
pubmed: 19327042 doi: 10.1517/17425240902806383
Chen Y, Liu L. Modern methods for delivery of drugs across the blood–brain barrier. Adv Drug Deliv Rev. 2012;64(7):640–65.
pubmed: 22154620 doi: 10.1016/j.addr.2011.11.010
Bhowmik A, Khan R, Ghosh MK. Blood brain barrier: a challenge for effectual therapy of brain tumors. BioMed Res Int. 2015;2015(1):20.
Hawkins BT, Davis TP. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev. 2005;57(2):173–85.
pubmed: 15914466 doi: 10.1124/pr.57.2.4
Pardridge WM. Drug transport across the blood–brain barrier. J Cereb Blood Flow Metab. 2012;32(11):1959–72.
pubmed: 22929442 pmcid: 3494002 doi: 10.1038/jcbfm.2012.126
Hartsock A, Nelson WJ. Adherens and tight junctions: structure, function and connections to the actin cytoskeleton. Biochimica et Biophysica Acta (BBA) Biomembranes. 2008;1778(3):660–9.
pubmed: 17854762 doi: 10.1016/j.bbamem.2007.07.012
Daneman R, Prat A. The blood–brain barrier. Cold Spring Harb Perspect Biol. 2015;7(1):a020412.
pubmed: 25561720 pmcid: 4292164 doi: 10.1101/cshperspect.a020412
Ballabh P, Braun A, Nedergaard M. The blood–brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol Dis. 2004;16(1):1–13.
pubmed: 15207256 doi: 10.1016/j.nbd.2003.12.016
Anderson JM, Van Itallie CM. Physiology and function of the tight junction. Cold Spring Harb Perspect Biol. 2009;1(2):a002584.
pubmed: 20066090 pmcid: 2742087 doi: 10.1101/cshperspect.a002584
Wolburg H, Lippoldt A. Tight junctions of the blood–brain barrier: development, composition and regulation. Vascul Pharmacol. 2002;38(6):323–37.
pubmed: 12529927 doi: 10.1016/S1537-1891(02)00200-8
Davies DC. Blood–brain barrier breakdown in septic encephalopathy and brain tumours. J Anat. 2002;200(6):639–46.
pubmed: 12162731 pmcid: 1570752 doi: 10.1046/j.1469-7580.2002.00065.x
Meewes C, et al. Molecular biologic and scintigraphic analyses of somatostatin receptor-negative meningiomas. J Nucl Med. 2001;42(9):1338–45.
pubmed: 11535722
Leten C, et al. In vivo and ex vivo assessment of the blood brain barrier integrity in different glioblastoma animal models. J Neurooncol. 2014;119(2):297–306.
pubmed: 24990826 doi: 10.1007/s11060-014-1514-2
Bette S, et al. Safe brain tumor resection does not depend on surgery alone-role of hemodynamics. Sci Rep. 2017;7(1):1–8.
doi: 10.1038/s41598-017-05767-2
Lampson LA. Brain tumor immunotherapy: seeing the brain in the body. Drug Discovery Today. 2013;18(7–8):399–406.
pubmed: 23195329 doi: 10.1016/j.drudis.2012.11.007
Yang Z, et al. Intensity-modulated radiotherapy for gliomas: dosimetric effects of changes in gross tumor volume on organs at risk and healthy brain tissue. Onco Targets Ther. 2016;9:3545.
pubmed: 27366091 pmcid: 4914054
Karimipour K, et al. Spiropyran-based photoswitchable acrylic nanofibers: a stimuli-responsive substrate for light controlled C6 glioma cells attachment/detachment. Colloids Surf, B. 2021;203:111731.
doi: 10.1016/j.colsurfb.2021.111731
Kiamohammadi L, et al. Physical and biological properties of 5-fluorouracil polymer-coated magnetite nanographene oxide as a new thermosensitizer for alternative magnetic hyperthermia and a magnetic resonance imaging contrast agent: in vitro and in vivo study. ACS Omega. 2021;6(31):20192–204.
pubmed: 34395970 pmcid: 8358959 doi: 10.1021/acsomega.1c01763
Mirzaghavami PS, et al. Radio-sensitivity enhancement in HT29 cells through magnetic hyperthermia in combination with targeted nano-carrier of 5-Flourouracil. Mater Sci Eng C. 2021;124: 112043.
doi: 10.1016/j.msec.2021.112043
Ghaznavi H, et al. An updated review on implications of autophagy and apoptosis in tumorigenesis: possible alterations in autophagy through engineered nanomaterials and their importance in Cancer therapy. Mol Pharmacol. 2021;100(2):119–43.
pubmed: 33990406 doi: 10.1124/molpharm.121.000234
Lungare S, Hallam K, Badhan RKS. Phytochemical-loaded mesoporous silica nanoparticles for nose-to-brain olfactory drug delivery. Int J Pharm. 2016;513(1–2):280–93.
pubmed: 27633279 doi: 10.1016/j.ijpharm.2016.09.042
Changizi O, et al. Enhanced radiosensitivity of LNCaP prostate cancer cell line by gold-photoactive nanoparticles modified with folic acid. Photodiagn Photodyn Ther. 2020;29: 101602.
doi: 10.1016/j.pdpdt.2019.101602
Mo J, et al. Tailoring particle size of mesoporous silica nanosystem to antagonize glioblastoma and overcome blood-brain Barrier. ACS Appl Mater Interfaces. 2016;8(11):6811–25.
pubmed: 26911360 doi: 10.1021/acsami.5b11730
You Y, et al. Tailored mesoporous silica nanosystem with enhanced permeability of the blood-brain barrier to antagonize glioblastoma. J Mater Chem B. 2016;4(36):5980–90.
pubmed: 32263487 doi: 10.1039/C6TB01329E
Fujishima A, Rao TN, Tryk DA. Titanium dioxide photocatalysis. J Photochem Photobiol, C. 2000;1(1):1–21.
doi: 10.1016/S1389-5567(00)00002-2
Lee YS, et al. Inhibitor of differentiation 1 (Id1) expression attenuates the degree of TiO2-induced cytotoxicity in H1299 non-small cell lung cancer cells. Toxicol Lett. 2009;189(3):191–9.
pubmed: 19486931 doi: 10.1016/j.toxlet.2009.05.019
Wang JJ, Sanderson BJS, Wang H. Cyto-and genotoxicity of ultrafine TiO2 particles in cultured human lymphoblastoid cells. Mutation Res/Genet Toxicol Env Mutagenesis. 2007;628(2):99–106.
doi: 10.1016/j.mrgentox.2006.12.003
Wang C, et al. Induction of cytotoxicity by photoexcitation of TiO2 can prolong survival in glioma-bearing mice. Mol Biol Rep. 2011;38(1):523–30.
pubmed: 20352345 doi: 10.1007/s11033-010-0136-9
You Y, et al. Designing dual-functionalized carbon nanotubes with high blood-brain-barrier permeability for precise orthotopic glioma therapy. Dalton Trans. 2019;48(5):1569–73.
pubmed: 30499579 doi: 10.1039/C8DT03948H
Ren J, et al. The targeted delivery of anticancer drugs to brain glioma by PEGylated oxidized multi-walled carbon nanotubes modified with angiopep-2. Biomaterials. 2012;33(11):3324–33.
pubmed: 22281423 doi: 10.1016/j.biomaterials.2012.01.025
Stephen ZR, et al. Redox-responsive magnetic nanoparticle for targeted convection-enhanced delivery of O 6-benzylguanine to brain tumors. ACS Nano. 2014;8(10):10383–95.
pubmed: 25247850 pmcid: 4212796 doi: 10.1021/nn503735w
Chertok B, David AE, Yang VC. Polyethyleneimine-modified iron oxide nanoparticles for brain tumor drug delivery using magnetic targeting and intra-carotid administration. Biomaterials. 2010;31(24):6317–24.
pubmed: 20494439 pmcid: 2896060 doi: 10.1016/j.biomaterials.2010.04.043
Lee J-H, et al. Exchange-coupled magnetic nanoparticles for efficient heat induction. Nat Nanotechnol. 2011;6(7):418–22.
pubmed: 21706024 doi: 10.1038/nnano.2011.95
Liu XL, et al. Magnetic vortex nanorings: a new class of hyperthermia agent for highly efficient in vivo regression of tumors. Adv Mater. 2015;27(11):1939–44.
pubmed: 25655680 doi: 10.1002/adma.201405036
Ma X, et al. Fe3O4-Pd Janus nanoparticles with amplified dual-mode hyperthermia and enhanced ROS generation for breast cancer treatment. Nanoscale Horizons. 2019;4(6):1450–9.
doi: 10.1039/C9NH00233B
Thiesen B, Jordan A. Clinical applications of magnetic nanoparticles for hyperthermia. Int J Hyperth. 2008;24(6):467–74.
doi: 10.1080/02656730802104757
Shah BP, et al. Core–shell nanoparticle-based peptide therapeutics and combined hyperthermia for enhanced cancer cell apoptosis. ACS Nano. 2014;8(9):9379–87.
pubmed: 25133971 pmcid: 4174096 doi: 10.1021/nn503431x
Sanz B, et al. Magnetic hyperthermia enhances cell toxicity with respect to exogenous heating. Biomaterials. 2017;114:62–70.
pubmed: 27846403 doi: 10.1016/j.biomaterials.2016.11.008
Hamdous Y, et al. Biocompatible coated magnetosome minerals with various organization and cellular interaction properties induce cytotoxicity towards RG-2 and GL-261 glioma cells in the presence of an alternating magnetic field. J Nanobiotechnol. 2017;15(1):1–18.
doi: 10.1186/s12951-017-0293-2
Vigderman L, Zubarev ER. Therapeutic platforms based on gold nanoparticles and their covalent conjugates with drug molecules. Adv Drug Deliv Rev. 2013;65(5):663–76.
pubmed: 22613038 doi: 10.1016/j.addr.2012.05.004
Cheng Y, et al. Blood-brain barrier permeable gold nanoparticles: an efficient delivery platform for enhanced malignant glioma therapy and imaging. Small. 2014;10(24):5137–50.
pubmed: 25104165 pmcid: 4268041 doi: 10.1002/smll.201400654
Bhunia S, et al. Large amino acid transporter 1 selective liposomes of l-DOPA functionalized amphiphile for combating glioblastoma. Mol Pharm. 2017;14(11):3834–47.
pubmed: 28958145 doi: 10.1021/acs.molpharmaceut.7b00569
Shaw TK, et al. Successful delivery of docetaxel to rat brain using experimentally developed nanoliposome: a treatment strategy for brain tumor. Drug Delivery. 2017;24(1):346–57.
pubmed: 28165821 pmcid: 8240984 doi: 10.1080/10717544.2016.1253798
Rehman M, et al. Enhanced blood brain barrier permeability and glioblastoma cell targeting via thermoresponsive lipid nanoparticles. Nanoscale. 2017;9(40):15434–40.
pubmed: 28976512 doi: 10.1039/C7NR05216B
Guerrero-Cázares H, et al. Biodegradable polymeric nanoparticles show high efficacy and specificity at DNA delivery to human glioblastoma in vitro and in vivo. ACS Nano. 2014;8(5):5141–53.
pubmed: 24766032 pmcid: 4046784 doi: 10.1021/nn501197v
Thakkar JP, et al. Epidemiologic and molecular prognostic review of glioblastomagbm epidemiology and biomarkers. Cancer Epidemiol Biomark Prev. 2014;23(10):1985–96.
doi: 10.1158/1055-9965.EPI-14-0275
Tivnan A, et al. Anti-GD2-ch14. 18/CHO coated nanoparticles mediate glioblastoma (GBM)-specific delivery of the aromatase inhibitor, Letrozole, reducing proliferation, migration and chemoresistance in patient-derived GBM tumor cells. Oncotarget. 2017;8(10):16605.
pubmed: 28178667 pmcid: 5369988 doi: 10.18632/oncotarget.15073
Meteoglu I, Erdemir A. Genistein and Temozolomide-loaded polymeric nanoparticles: a synergistic approach for improved anti-tumor efficacy against glioblastoma. Process Biochem. 2021;110:9–18.
doi: 10.1016/j.procbio.2021.07.015
Sousa F, et al. Enhanced anti-angiogenic effects of bevacizumab in glioblastoma treatment upon intranasal administration in polymeric nanoparticles. J Control Release. 2019;309:37–47.
pubmed: 31344424 doi: 10.1016/j.jconrel.2019.07.033
Spector R. Nature and consequences of mammalian brain and CSF efflux transporters: four decades of progress. J Neurochem. 2010;112(1):13–23.
pubmed: 19860860 doi: 10.1111/j.1471-4159.2009.06451.x
Chung EJ, et al. Fibrin-binding, peptide amphiphile micelles for targeting glioblastoma. Biomaterials. 2014;35(4):1249–56.
pubmed: 24211079 doi: 10.1016/j.biomaterials.2013.10.064
Hashempour Alamdari N, et al. 2017 Gd3+-asparagine-anionic linear globular dendrimer second-generation G2 complexes: novel nanobiohybrid theranostics. Contrast Med Mol Imaging. 2017;1:19.
Liko F, Hindre F, Fernandez-Megia E. Dendrimers as innovative radiopharmaceuticals in cancer radionanotherapy. Biomacromol. 2016;17(10):3103–14.
doi: 10.1021/acs.biomac.6b00929
McMahon MT, Bulte JWM. Two decades of dendrimers as versatile MRI agents: a tale with and without metals. Wiley Interdisciplinary Rev Nanomed Nanobiotechnol. 2018;10(3): e1496.
doi: 10.1002/wnan.1496
Zhao L, et al. Chlorotoxin-conjugated multifunctional dendrimers labeled with radionuclide 131I for single photon emission computed tomography imaging and radiotherapy of gliomas. ACS Appl Mater Interfaces. 2015;7(35):19798–808.
pubmed: 26291070 doi: 10.1021/acsami.5b05836
Li Y, et al. A dual-targeting nanocarrier based on poly (amidoamine) dendrimers conjugated with transferrin and tamoxifen for treating brain gliomas. Biomaterials. 2012;33(15):3899–908.
pubmed: 22364698 doi: 10.1016/j.biomaterials.2012.02.004
Gallien J, et al. Curcumin Loaded Dendrimers Specifically Reduce Viability of Glioblastoma Cell Lines. Molecules. 2021;26(19):6050.
pubmed: 34641594 pmcid: 8512379 doi: 10.3390/molecules26196050
Maeda H, Sawa T, Konno T. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J Control Release. 2001;74(1–3):47–61.
pubmed: 11489482 doi: 10.1016/S0168-3659(01)00309-1
Yuan F, et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Can Res. 1995;55(17):3752–6.
Bertrand N, et al. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev. 2014;66:2–25.
pubmed: 24270007 doi: 10.1016/j.addr.2013.11.009
Ruoslahti E. Specialization of tumour vasculature. Nat Rev Cancer. 2002;2(2):83–90.
pubmed: 12635171 doi: 10.1038/nrc724
Shirvalilou S, et al. Enhancement radiation-induced apoptosis in C6 glioma tumor-bearing rats via pH-responsive magnetic graphene oxide nanocarrier. J Photochem Photobiol, B. 2020;205:111827.
pubmed: 32120183 doi: 10.1016/j.jphotobiol.2020.111827
Zong Z, et al. Self-assembled angiopep-2 modified lipid-poly (hypoxic radiosensitized polyprodrug) nanoparticles delivery TMZ for glioma synergistic TMZ and RT therapy. Drug Delivery. 2019;26(1):34–44.
pubmed: 30744436 pmcid: 6394306 doi: 10.1080/10717544.2018.1534897
Lu F, et al. Angiopep-2-conjugated poly (ethylene glycol)-co-poly (ε-caprolactone) polymersomes for dual-targeting drug delivery to glioma in rats. Int J Nanomed. 2017;12:2117.
doi: 10.2147/IJN.S123422
Wang X, et al. Angiopep-2/IP10-EGFRvIIIscFv modified nanoparticles and CTL synergistically inhibit malignant glioblastoma. Sci Rep. 2018;8(1):12827.
pubmed: 30150691 pmcid: 6110710 doi: 10.1038/s41598-018-30072-x
Huang J-L, et al. Lipoprotein-biomimetic nanostructure enables efficient targeting delivery of siRNA to Ras-activated glioblastoma cells via macropinocytosis. Nat Commun. 2017;8(1):15144.
pubmed: 28489075 pmcid: 5436231 doi: 10.1038/ncomms15144
Jiang Y, et al. Apolipoprotein E peptide-directed chimeric polymersomes mediate an ultrahigh-efficiency targeted protein therapy for glioblastoma. ACS Nano. 2018;12(11):11070–9.
pubmed: 30395440 doi: 10.1021/acsnano.8b05265
Rajora M, et al. Correction: tailored theranostic apolipoprotein E3 porphyrin-lipid nanoparticles target glioblastoma. Chem Sci. 2017;8(8):5803–5803.
pubmed: 30294416 pmcid: 6157424 doi: 10.1039/C7SC90047C
Mao J, et al. EGFR/EGFRvIII dual-targeting peptide-mediated drug delivery for enhanced glioma therapy. ACS Appl Mater Interfaces. 2017;9(29):24462–75.
pubmed: 28685576 doi: 10.1021/acsami.7b05617
Zhang J, et al. Lactoferrin-and RGD-comodified, temozolomide and vincristine-coloaded nanostructured lipid carriers for gliomatosis cerebri combination therapy. Int J Nanomed. 2018;13:3039.
doi: 10.2147/IJN.S161163
Lam FC, et al. Enhanced efficacy of combined temozolomide and bromodomain inhibitor therapy for gliomas using targeted nanoparticles. Nat Commun. 2018;9(1):1991.
pubmed: 29777137 pmcid: 5959860 doi: 10.1038/s41467-018-04315-4
Wang X, et al. Cell-penetrating peptide and transferrin co-modified liposomes for targeted therapy of glioma. Molecules. 2019;24(19):3540.
pubmed: 31574945 pmcid: 6804123 doi: 10.3390/molecules24193540
Yu Y, et al. Efficacy of temozolomide-conjugated gold nanoparticle photothermal therapy of drug-resistant glioblastoma and its mechanism study. Mol Pharm. 2022;19(4):1219–29.
pubmed: 35262365 doi: 10.1021/acs.molpharmaceut.2c00083
Persano S, et al. Elucidating the innate immunological effects of mild magnetic hyperthermia on U87 human glioblastoma cells: an in vitro study. Pharmaceutics. 2021;13(10):1668.
pubmed: 34683961 pmcid: 8537446 doi: 10.3390/pharmaceutics13101668
Bae YH, Park K. Targeted drug delivery to tumors: myths, reality and possibility. J Control Release. 2011;153(3):198.
pubmed: 21663778 pmcid: 3272876 doi: 10.1016/j.jconrel.2011.06.001
Matsumura, Y. and H. Maeda, A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer research, 1986. 46(12_Part_1): p. 6387–6392.
Irajirad R, et al. Combined thermo-chemotherapy of cancer using 1 MHz ultrasound waves and a cisplatin-loaded sonosensitizing nanoplatform: an in vivo study. Cancer Chemother Pharmacol. 2019;84:1315–21.
pubmed: 31559450 doi: 10.1007/s00280-019-03961-9
Albanese A, Tang PS, Chan WCW. The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu Rev Biomed Eng. 2012;14(1):1–16.
pubmed: 22524388 doi: 10.1146/annurev-bioeng-071811-150124
Chou LYT, Ming K, Chan WCW. Strategies for the intracellular delivery of nanoparticles. Chem Soc Rev. 2011;40(1):233–45.
pubmed: 20886124 doi: 10.1039/C0CS00003E
He C, et al. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials. 2010;31(13):3657–66.
pubmed: 20138662 doi: 10.1016/j.biomaterials.2010.01.065
Alexis F, et al. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm. 2008;5(4):505–15.
pubmed: 18672949 pmcid: 2663893 doi: 10.1021/mp800051m
Li Y, Kröger M, Liu WK. Endocytosis of PEGylated nanoparticles accompanied by structural and free energy changes of the grafted polyethylene glycol. Biomaterials. 2014;35(30):8467–78.
pubmed: 25002266 doi: 10.1016/j.biomaterials.2014.06.032
Guo X, et al. Dual-responsive polymer micelles for target-cell-specific anticancer drug delivery. Chem Mater. 2014;26(15):4405–18.
doi: 10.1021/cm5012718
Oupicky D, et al. Importance of lateral and steric stabilization of polyelectrolyte gene delivery vectors for extended systemic circulation. Mol Ther. 2002;5(4):463–72.
pubmed: 11945074 doi: 10.1006/mthe.2002.0568
Li Y, Kröger M, Liu WK. Shape effect in cellular uptake of PEGylated nanoparticles: comparison between sphere, rod, cube and disk. Nanoscale. 2015;7(40):16631–46.
pubmed: 26204104 doi: 10.1039/C5NR02970H
Shen S, et al. Near-infrared light-responsive nanoparticles with thermosensitive yolk-shell structure for multimodal imaging and chemo-photothermal therapy of tumor. Nanomed Nanotechnol, Biol Med. 2017;13(5):1607–16.
doi: 10.1016/j.nano.2017.02.014
Kircher MF, et al. A brain tumor molecular imaging strategy using a new triple-modality MRI-photoacoustic-Raman nanoparticle. Nat Med. 2012;18(5):829–34.
pubmed: 22504484 pmcid: 3422133 doi: 10.1038/nm.2721
Wolburg H, et al. The disturbed blood–brain barrier in human glioblastoma. Mol Aspects Med. 2012;33(5–6):579–89.
pubmed: 22387049 doi: 10.1016/j.mam.2012.02.003
Tzeng SY, Green JJ. Therapeutic nanomedicine for brain cancer. Ther Deliv. 2013;4(6):687–704.
pubmed: 23738667 doi: 10.4155/tde.13.38
Baumann BC, et al. Enhancing the efficacy of drug-loaded nanocarriers against brain tumors by targeted radiation therapy. Oncotarget. 2013;4(1):64.
pubmed: 23296073 pmcid: 3702208 doi: 10.18632/oncotarget.777
Liu G, et al. Transferrin modified graphene oxide for glioma-targeted drug delivery: in vitro and in vivo evaluations. ACS Appl Mater Interfaces. 2013;5(15):6909–14.
pubmed: 23883622 doi: 10.1021/am402128s
Van Driel PBAA, et al. EGFR targeted nanobody–photosensitizer conjugates for photodynamic therapy in a pre-clinical model of head and neck cancer. J Control Release. 2016;229:93–105.
pubmed: 26988602 pmcid: 7116242 doi: 10.1016/j.jconrel.2016.03.014
Afzalipour R, et al. Dual-targeting temozolomide loaded in folate-conjugated magnetic triblock copolymer nanoparticles to improve the therapeutic efficiency of rat brain gliomas. ACS Biomater Sci Eng. 2019;5(11):6000–11.
pubmed: 33405722 doi: 10.1021/acsbiomaterials.9b00856
Schiffer D, et al. On the origin and growth of gliomas. Anticancer Res. 2010;30(6):1977–98.
pubmed: 20651342
Allhenn D, Shetab Boushehri MA, Lamprecht A. Drug delivery strategies for the treatment of malignant gliomas. Int J Pharma. 2012;436(1):299–310.
doi: 10.1016/j.ijpharm.2012.06.025
Zhang T-T, et al. Strategies for transporting nanoparticles across the blood–brain barrier. Biomater Sci. 2016;4(2):219–29.
pubmed: 26646694 doi: 10.1039/C5BM00383K
Arami H, et al. Chitosan-coated iron oxide nanoparticles for molecular imaging and drug delivery. Chitosan Biomater. 2011;I:163–84.
doi: 10.1007/12_2011_121
Das D, Lin S. Double-coated poly (butylcynanoacrylate) nanoparticulate delivery systems for brain targeting of dalargin via oral administration. J Pharm Sci. 2005;94(6):1343–53.
pubmed: 15858853 doi: 10.1002/jps.20357
Georgieva JV, Hoekstra D, Zuhorn IS. Smuggling drugs into the brain: an overview of ligands targeting transcytosis for drug delivery across the blood–brain barrier. Pharmaceutics. 2014;6(4):557–83.
pubmed: 25407801 pmcid: 4279133 doi: 10.3390/pharmaceutics6040557
Kreuter J, et al. Direct evidence that polysorbate-80-coated poly (butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Pharm Res. 2003;20(3):409–16.
pubmed: 12669961 doi: 10.1023/A:1022604120952
Kreuter J, et al. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J Drug Target. 2002;10(4):317–25.
pubmed: 12164380 doi: 10.1080/10611860290031877
Xin H, et al. Anti-glioblastoma efficacy and safety of paclitaxel-loading angiopep-conjugated dual targeting PEG-PCL nanoparticles. Biomaterials. 2012;33(32):8167–76.
pubmed: 22889488 doi: 10.1016/j.biomaterials.2012.07.046
Li C, et al. Paclitaxel-loaded cholesterol-conjugated polyoxyethylene sorbitol oleate polymeric micelles for glioblastoma therapy across the blood–brain barrier. Polym Chem. 2015;6(14):2740–51.
doi: 10.1039/C4PY01422G
Yang X, et al. Transferrin receptor-targeted lipid nanoparticles for delivery of an antisense oligodeoxyribonucleotide against Bcl-2. Mol Pharm. 2009;6(1):221–30.
pubmed: 19183107 pmcid: 3608852 doi: 10.1021/mp800149s
Yhee JY, et al. Tumor-targeting transferrin nanoparticles for systemic polymerized siRNA delivery in tumor-bearing mice. Bioconjug Chem. 2013;24(11):1850–60.
pubmed: 24107100 doi: 10.1021/bc400226b
Dixit S, et al. Transferrin receptor-targeted theranostic gold nanoparticles for photosensitizer delivery in brain tumors. Nanoscale. 2015;7(5):1782–90.
pubmed: 25519743 pmcid: 4437576 doi: 10.1039/C4NR04853A
Porru M, et al. Medical treatment of orthotopic glioblastoma with transferrin-conjugated nanoparticles encapsulating zoledronic acid. Oncotarget. 2014;5(21):10446.
pubmed: 25431953 pmcid: 4279385 doi: 10.18632/oncotarget.2182
Liu DZ, et al. The enhancement of siPLK1 penetration across BBB and its anti glioblastoma activity in vivo by magnet and transferrin co-modified nanoparticle. Nanomed Nanotechnol Biol Med. 2018;14(3):991–1003.
doi: 10.1016/j.nano.2018.01.004
Hu K, et al. Lactoferrin-conjugated PEG–PLA nanoparticles with improved brain delivery: in vitro and in vivo evaluations. J Control Release. 2009;134(1):55–61.
pubmed: 19038299 doi: 10.1016/j.jconrel.2008.10.016
Hu K, et al. Lactoferrin conjugated PEG-PLGA nanoparticles for brain delivery: preparation, characterization and efficacy in Parkinson’s disease. Int J Pharm. 2011;415(1–2):273–83.
pubmed: 21651967 doi: 10.1016/j.ijpharm.2011.05.062
Yu Y, et al. The proton permeability of self-assembled polymersomes and their neuroprotection by enhancing a neuroprotective peptide across the blood–brain barrier after modification with lactoferrin. Nanoscale. 2014;6(6):3250–8.
pubmed: 24503971 doi: 10.1039/C3NR05196J
Ji B, et al. Pharmacokinetics and brain uptake of lactoferrin in rats. Life Sci. 2006;78(8):851–5.
pubmed: 16165165 doi: 10.1016/j.lfs.2005.05.085
Boado RJ, et al. Blood-brain barrier molecular trojan horse enables imaging of brain uptake of radioiodinated recombinant protein in the rhesus monkey. Bioconjug Chem. 2013;24(10):1741–9.
pubmed: 24059813 doi: 10.1021/bc400319d
Boado RJ, et al. Insulin receptor antibody–sulfamidase fusion protein penetrates the primate blood–brain barrier and reduces glycosoaminoglycans in Sanfilippo type A cells. Mol Pharm. 2014;11(8):2928–34.
pubmed: 24949884 pmcid: 4137762 doi: 10.1021/mp500258p
Dieu L-H, et al. Polymersomes conjugated to 83–14 monoclonal antibodies: in vitro targeting of brain capillary endothelial cells. Eur J Pharm Biopharm. 2014;88(2):316–24.
pubmed: 24929212 doi: 10.1016/j.ejpb.2014.05.021
Kuo YC, Shih-Huang CY. Solid lipid nanoparticles carrying chemotherapeutic drug across the blood-brain barrier through insulin receptor-mediated pathway. J Drug Target. 2013;21(8):730–8.
pubmed: 23815407 doi: 10.3109/1061186X.2013.812094
Shilo M, et al. Transport of nanoparticles through the blood–brain barrier for imaging and therapeutic applications. Nanoscale. 2014;6(4):2146–52.
pubmed: 24362586 doi: 10.1039/C3NR04878K
Ulbrich K, Knobloch T, Kreuter J. Targeting the insulin receptor: nanoparticles for drug delivery across the blood–brain barrier (BBB). J Drug Target. 2011;19(2):125–32.
pubmed: 20387992 doi: 10.3109/10611861003734001
El-Sayed HXJPK, IH, et al. Plasmonic photothermal therapy (PPTT) using gold nanoparticles. Lasers Med Sci. 2008;23(3):217.
pubmed: 17674122 doi: 10.1007/s10103-007-0470-x
Persano, S., et al., Elucidating the innate immunological effects of mild magnetic hyperthermia on U87 human glioblastoma cells: An in vitro study. Pharmaceutics, 2021. 13(10).
Gupta R, Sharma D. Manganese-doped magnetic nanoclusters for hyperthermia and photothermal glioblastoma therapy. ACS Appl Nano Mater. 2020;3(2):2026–37.
doi: 10.1021/acsanm.0c00121
Whittle JR, et al. First in human nanotechnology doxorubicin delivery system to target epidermal growth factor receptors in recurrent glioblastoma. J Clin Neurosci. 2015;22(12):1889–94.
pubmed: 26279503 doi: 10.1016/j.jocn.2015.06.005
Maier-Hauff K, et al. Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. J Neurooncol. 2011;103(2):317–24.
pubmed: 20845061 doi: 10.1007/s11060-010-0389-0
Ananda S, et al. Phase 2 trial of temozolomide and pegylated liposomal doxorubicin in the treatment of patients with glioblastoma multiforme following concurrent radiotherapy and chemotherapy. J Clin Neurosci. 2011;18(11):1444–8.
pubmed: 21813279 doi: 10.1016/j.jocn.2011.02.026
Beier CP, et al. RNOP-09: Pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma - a phase II study. BMC Cancer. 2009;9:308–408.
pubmed: 19725960 pmcid: 2749868 doi: 10.1186/1471-2407-9-308
Menei P, et al. Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of malignant glioma: a randomized phase II trial. Neurosurgery. 2005;56(2):242–7.
pubmed: 15670372 doi: 10.1227/01.NEU.0000144982.82068.A2
Ren H, et al. Immunogene therapy of recurrent glioblastoma multiforme with a liposomally encapsulated replication-incompetent Semliki forest virus vector carrying the human interleukin-12 gene—a phase I/II clinical protocol. J Neurooncol. 2003;64(1–2):147–54.
pubmed: 12952295 doi: 10.1007/BF02700029
Ragelle H, et al. Nanoparticle-based drug delivery systems: a commercial and regulatory outlook as the field matures. Expert Opin Drug Deliv. 2017;14(7):851–64.
pubmed: 27730820 doi: 10.1080/17425247.2016.1244187
Goldberg MS, et al. Biotargeted nanomedicines for cancer: six tenets before you begin. Nanomedicine. 2013;8(2):299–308.
pubmed: 23394158 doi: 10.2217/nnm.13.3
Owonikoko TK, et al. Current approaches to the treatment of metastatic brain tumours. Nat Rev Clin Oncol. 2014;11(4):203–22.
pubmed: 24569448 pmcid: 4041037 doi: 10.1038/nrclinonc.2014.25
Weaver M, Laske DW. Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J Neurooncol. 2003;65:3–14.
pubmed: 14649881 doi: 10.1023/A:1026246500788
Fabel K, et al. Long-term stabilization in patients with malignant glioma after treatment with liposomal doxorubicin. Cancer Inter Int J Am Cancer Soc. 2001;92(7):1936–42.
Hau P, et al. Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma. Cancer Inter Int J Am Cancer Soc. 2004;100(6):1199–207.
Beier CP, et al. RNOP-09: pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma-a phase II study. BMC Cancer. 2009;9:1–10.
doi: 10.1186/1471-2407-9-308
Ferrari M, Philibert M, Sanhai W. Nanomedicine and society. Clin Pharmacol Ther. 2009;85(5):466–7.
pubmed: 19381150 doi: 10.1038/clpt.2008.276
Nguyen TT, et al. Nanotechnology-based drug delivery for central nervous system disorders. Biomed Pharmacother. 2021;143:112117.
pubmed: 34479020 doi: 10.1016/j.biopha.2021.112117
Sanhai WR, et al. Seven challenges for nanomedicine. Nat Nanotechnol. 2008;3(5):242–4.
pubmed: 18654511 doi: 10.1038/nnano.2008.114
Kumar V, et al. Nanotechnology: nanomedicine, nanotoxicity and future challenges. Nanosci Nanotechnol-Asia. 2019;9(1):64–78.
doi: 10.2174/2210681208666180125143953

Auteurs

Sakine Shirvalilou (S)

Finetech in Medicine Research Center, Department of Medical Physics, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Department of Medical Physics, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.

Samideh Khoei (S)

Finetech in Medicine Research Center, Department of Medical Physics, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Department of Medical Physics, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.

Reza Afzalipour (R)

Molecular Medicine Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran. reza.afzalipour@hums.ac.ir.
Department of Radiology, Faculty of Para-Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, Iran. reza.afzalipour@hums.ac.ir.
ORCID: 0000-0001-5646-7564

Habib Ghaznavi (H)

Pharmacology Research Center, Zahedan University of Medical Sciences, Zahedan, Iran.

Milad Shirvaliloo (M)

Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
Future Science Group, Unitec House, 2 Albert Place, London, N3 1QB, UK.

Zahra Derakhti (Z)

Department of Medical Physics, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.

Roghayeh Sheervalilou (R)

Pharmacology Research Center, Zahedan University of Medical Sciences, Zahedan, Iran. sheervalilour@tbzmed.ac.ir.
ORCID: 0000-0001-7996-845X

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Targeting the undruggable in glioblastoma...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Tumeurs du tissu nerveux › Tumeurs neuroectodermiques › Tumeurs neuroépitheliales › Gliome › Astrocytome › Glioblastome › Targeting the undruggable in glioblastoma...
questionsmedicales.fr › Maladies du système nerveux › Tumeurs du système nerveux › Tumeurs du système nerveux central › Tumeurs du cerveau › Targeting the undruggable in glioblastoma...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Systèmes de délivrance de médicaments › Targeting the undruggable in glioblastoma...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Targeting the undruggable in glioblastoma...
questionsmedicales.fr › Système nerveux › Système nerveux central › Encéphale › Barrière hémato-encéphalique › Targeting the undruggable in glioblastoma...
questionsmedicales.fr › Technologie, industrie et agriculture › Produits manufacturés › Nanostructures › Nanoparticules › Targeting the undruggable in glioblastoma...
questionsmedicales.fr › Eucaryotes › Animaux › Targeting the undruggable in glioblastoma...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Systèmes de délivrance de médicaments › Vecteurs de médicaments › Système d'administration de médicaments à base de nanoparticules › Targeting the undruggable in glioblastoma...
questionsmedicales.fr › Techniques d'investigation › Techniques génétiques › Génie génétique › Thérapie génétique › Targeting the undruggable in glioblastoma...